CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS
The invention relates to the use of one or more cannabinoids, particularly THC and/or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). The non-cannabinoid chemotherapeutic agent may be a selective estrogen receptor modulator or an alkylating agent.
1 - 20 . (canceled)
21 . A method for treating glioma in a human in need thereof, comprising: administering to the human:
(i) tetrahydrocannabinol (THC) and cannabidiol (CBD), wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:20; and
(ii) temozolomide.
22 . The method of claim 21 , wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:5.
23 . The method of claim 21 , wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:2.
24 . The method of claim 21 , wherein a botanical drug substance comprising the THC and CBD is administered to the human.
25 . The method of claim 21 , wherein the human has a glioma tumour.
26 . The method of claim 25 , wherein the glioma tumour is glioblastoma multiforme (GBM).
27 . The method of claim 21 , wherein the THC and CBD, and the temozolomide are administered separately.
28 . The method of claim 21 , wherein the THC and CBD, and the temozolomide are administered sequentially.
29 . The method of claim 21 , wherein the THC and CBD, and the temozolomide are administered simultaneously.
30 . A method for increasing the efficacy of temozolomide in inhibiting cancer cell growth or reducing cancer cell viability comprising: administering to a human having a glioma tumour:
(i) a botanical drug substance comprising tetrahydrocannabinol (THC) and cannabidiol (CBD), wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:20; and
(ii) temozolomide.
31 . The method of claim 30 , wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:5.
32 . The method of claim 30 , wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:2.
33 . The method of claim 30 , wherein the glioma tumour is a glioblastoma multiforme (GBM).
34 . The method of claim 30 , wherein the THC and CBD, and the temozolomide are administered separately.
35 . The method of claim 30 , wherein the THC and CBD, and the temozolomide are administered sequentially.
36 . The method of claim 30 , wherein the THC and CBD, and the temozolomide are administered simultaneously.